Critical Review

Computational Models of the Heart and Their Use in Assessing the Actions of Drugs

Denis Noble1,*

1Department of Physiology, Anatomy and Genetics, University of Oxford, Parks Road, Oxford, OX1 3PT, UK

Received July 20, 2007

Abstract. Models of cardiac cells are sufficiently well developed to answer questions concerning the actions of drugs on repolarization and the initiation of arrhythmias. These models can be used to characterize drug-receptor action profiles that would be expected to avoid arrhythmia and so help to identify drugs that may be safer. Several examples of such action profiles are presented here, including a recently-developed blocker of persistent sodium current, ranolazine. The models have also been incorporated into tissue and organ models that enable arrhythmia to be modelled also at these levels. Work at these levels can reproduce both re-entrant arrhythmia and fibrillation.

Keywords: cardiac cell model, cardiac organ model, repolarization, early after-depolarization (EAD), delayed after-depolarization (DAD)

Introduction

Computational models of heart cells have a long history of development during which they have become perhaps the most detailed cell models available today. Over 100 such models are listed on the CellML website (www.cellml.org), which means that they can be downloaded and used immediately with software that is CellML compatible (e.g. http://cor.physiol.ox.ac.uk/).

The first models using equations for the kinetics of ion channels were created in 1960 (1, 2), and they were based on early experimental work on the potassium channels in heart muscle (3-5), and on the groundbreaking work of Hodgkin and Huxley who created the first nerve axon model (6).

The experiments with Otto Hutter led to the first classification of potassium channels in the heart into those showing very rapid inward-rectification (iK1) and those showing delayed (time-dependent) outward rectification (iK). As shown in Fig. 1, these two types of channel play very different roles in depolarization and repolarization. Because iK1 changes rapidly, the trajectory first follows its voltage-dependence. As a consequence, the potassium conductance becomes very low at the beginning of a ventricular action potential. This can be seen as an energy-conserving device since very small sodium and calcium conductances are then sufficient to maintain the long plateau of the action potential, and less energy is required to restore the gradients of all these ions following each heartbeat.

Repolarization depends on the slow activation of iK channels. As I will show later in this article, the repolarization process is fragile. Many drugs can interfere with repolarization. In fact such side-effects of drugs on the heart are frequent and serious. According to some estimates around 40% of all new pharmaceutical compounds have such effects. They can cause serious arrhythmias that may be fatal. The cost to the industry is large. Withdrawal of a drug after approval represents a lost investment of more than $1 billion before one even begins to count lost sales and share values. A solution to this problem would therefore be beneficial to everyone. It would make the industry more successful, since many of the compounds withdrawn, or which never even make it to the market for this kind of reason, are effective drugs in other respects. Moreover, the side effects may be experienced by much less than 1% of the patient population. For the vast majority of patients the drugs would be beneficial. Rescuing such drugs might therefore be worthwhile and discovering combinations of

*Corresponding author. denis.noble@physiol.ox.ac.uk
Published online in J-STAGE
doi: 10.1254/jphs.CR0070042
Invited article
actions that avoid the problem could improve the selection of lead compounds at an early stage.

It would benefit health care for other reasons too. One reason that drug prices are high is that health care systems have to bear the cost of industry failures as well as industry successes. Unfortunately, the failures greatly outnumber the successes, by around 50:1 according to some estimates. One analyst in the industry told me: “All you have to do is to decrease our attrition rate from around 98% to 96% and you would make us twice as successful.” So, simulation does not have to be 100% successful to have a major impact on drug development. Even if just a fraction of the insights gained are valuable, that could be enough to make a significant difference.

It is also important to emphasize that these insights can be of many different kinds. The dream of being able to use computer models as though they were the equivalent of experimental animals, or even substitute virtual humans, is a long way off. Even the most sophisticated of computer models of the heart may represent the functionality of only 2% of the gene and protein mechanisms involved, and many of those mechanisms need further refinement. Therefore, we are not yet in the position of the aircraft industry, which can simulate a whole aircraft with reliable predictive capability on its ability to fly and to carry out all the other functions required. However, that analogy also provides the clue to a more positive message. Insights from computer models of aircraft were valuable even before they replaced wind-tunnel experiments. Improving our quantitative understanding of complex interactions in biological systems, and refining the experimental approaches necessary to further refine the models, can have valuable practical spin-offs. In this article, I will show the extent to which simulation can help to address the cardiac arrhythmia problem.

Current methods for screening against arrhythmia

Of course, people have looked for biological markers to give at least early warning of possible cardiac problems. However, at present we are using very unreliable markers: QT and hERG. QT is the interval between the rapid QRS complex of the electrocardiogram, corresponding to the sharp depolarization wave as excitation spreads through the ventricle, and the T wave, which corresponds to repolarization. To a first approximation, therefore, the QT interval is a measure of the duration of the ventricular action potentials. Since some of the drugs that cause arrhythmic side-effects prolong the action potential, measuring QT, perhaps together with other markers, such as action on the repolarizing current \( i_{Kr} \) or one of its proteins hERG,
might identify the problem compounds. Measuring QT, right down to the last millisecond or two, has therefore become a refined technical art with many variations on how exactly to measure it. The T wave is hardly ever kind enough to give you a completely obvious point of measurement, so how to correct those measurements for unrelated variations, and how to automate all of this, has become necessary.

Unfortunately, the link between prolonged QT and arrhythmia is neither necessary nor sufficient. Some drugs cause arrhythmia without prolonging QT and some drugs that prolong QT do not cause arrhythmia. The QT interval is therefore a seriously flawed marker. A similar problem applies to hERG. Some drugs that prolong QT do cause arrhythmia. The answer lies in the quantities of electrical forces. Not only are the currents involved small, they are even smaller than one might expect because, once the fast depolarization phase is complete, the net membrane conductance is activated. Once the threshold for initiating the process has been reached, it is exceedingly difficult to stop it from running its full course. Depolarization is therefore extremely robust. By contrast, repolarization is brought about by very tiny currents resulting from a fine balance between almost equal depolarizing and repolarizing factors. Not only are the currents involved small, they are even smaller than one might expect because, once the last depolarization phase is complete, the net membrane conductance actually falls well below its resting value, a fact that was first discovered by Weidmann (7). This was a surprise since it is exactly the opposite result from that obtained during nerve excitation (8). It was the reconstruction of Cole and Curtis’ experimental result that formed one of the great successes of the Hodgkin-Huxley model of the nerve impulse (6). Reconstruction of Weidmann’s experimental data has also been a criterion for validating cardiac cell models (2, 9, 10).

The reason for this difference between heart and nerve is an evolutionary compromise of the form that I have called ‘nature’s pacts with the devil’ (11). These are what we, with hindsight, would call design faults, but which, from an evolutionary point of view, are the inevitable price paid for many successful developments. They resemble Faust’s pact with the devil in which Faust secured years of unlimited knowledge and power, but at the price of giving the devil his soul. The key to this kind of pact is that it is eventually fatal but for a long time it is of great benefit. This is just the kind of pact that nature stumbles upon when it finds a good combination of genes to transmit a function, at a price that may eventually be fatal. Evolution may take little notice of the fatality in individuals, particularly if it occurs well after the reproductive period of life. And evolution certainly did not anticipate the coming of the pharmaceutical industry.

The long-lasting cardiac action potential is a consequence of such an evolutionary compromise in the development of potassium currents in the heart. As we have seen, these channels can be divided into two classes: channels that close on depolarization, \( i_{K1} \), and channels that open during depolarization, including the various components of \( i_K \), and of the transient outward current, \( i_o \). At rest, \( i_{K1} \) is switched on and holds the resting potential at a very negative level, where the other K’ currents are switched off. On depolarization \( i_{K1} \) rapidly switches off, while the other currents take time to activate and to cause repolarization.

The biological advantage of this potassium channel system is that it saves energy (see Introduction). The energy required to pump ions back again during each cardiac cycle is minimized. Even with this economy, around 20% of the energy consumption of the heart is attributable to ion pumping. That figure would have been much larger without the \( i_{K1} \) mechanism. That is the good side of nature’s Faustian pact.

The bad side is that hERG, one of the proteins that forms the main component of \( i_K \), is highly promiscuous. The channel can be blocked by many pharmaceutical compounds. When that happens, repolarization fails and the action potential is followed by one or more waves of depolarization (Fig. 2). These can trigger cardiac arrhythmia that in some cases is fatal.

Figure 2 was produced by running the Noble_model_2000 CellML file within the modelling software COR (http://COR.physiol.ox.ac.uk). In this model 65% block of \( i_{K1} \) is sufficient to prevent smooth repolarization and to initiate a series of EADs. One of the inward currents involved in each depolarization is the L-type calcium channel.
current, $i_{CaL}$. The middle trace shows multiple reactivations of this current during each oscillation of membrane potential.

Many factors can interact with drugs to make this problem worse. These include genetic factors (see Fig. 3), such as mutations in sodium, potassium, and calcium channel genes, that predispose people to repolarization failure (13–15). This is the main explanation for the fact that drugs have this side effect do so in only a small fraction of the population. In principle, it should become possible to screen for such genetic predispositions to exclude such patients in clinical trials and to avoid treating them with drugs that interact in this way.

Avoiding the problem

Can drugs be designed to avoid this kind of problem?

Clearly, there is no way in which we can correct nature’s ‘mistake’ in evolving repolarization channels that are blocked by so many drugs. Dreams of doing so by genetic manipulation are not just unimaginably improbable dreams, they would also be unethical. We can never be sure that a gene that we have identified with one particular function might not also be involved in many others we do not know about (11). So, it is quite possible that the molecular properties that enable $i_{Kr}$ to perform its role in the heart are also those that predispose it to drug sensitivity. Therefore, the way forward is to design better drugs. That this can be done is illustrated in Fig. 4. This shows the same computation as in Fig. 2, but with the addition of a computation in which 65% block of the potassium channel was combined with 20% block of the L type calcium channels. The result is a smooth repolarization with no signs of EADs. Clearly, a multi-receptor drug with this combination of properties would be expected to avoid arrhythmia. Such compounds exist. This particular computation was of a compound BRL-32872 that has exactly this profile of action (17). Amiodarone, which is a multi-site drug, also includes this profile, to which we can also add inhibition of sodium-calcium exchange (18). This suggests that there may be many combinations of drug actions that could be effective. Drugs that include actions on persistent sodium current (19–22) are also in this category (23–25) – see Fig. 5.

Multiple cellular mechanisms of arrhythmia

EADs form just one of the several known cellular mechanisms of arrhythmia. DADs are a second mechanism. These consist in spontaneous depolarizations arising after repolarization is complete, and they are known to be caused by intracellular calcium oscillations in conditions of intracellular sodium overload. Such conditions are found in a variety of pathological states including heart failure and ischemic heart disease. The initial causes vary but the common mechanism is reduced energy available to pump sodium out of the cell via Na$^+$-K$^+$ ATPase (the sodium pump). Intracellular sodium therefore rises above its normal range (around 5–10) into a range (12–20 mM) that can cause arrhythmias. The processes involved are now understood well enough to model them (27). The rise in intracellular sodium acts via sodium-calcium exchange to cause a rise in intracellular calcium. Above a certain threshold, this can stimulate release of calcium from the sarcoplasmic reticulum via the same mechanism that underlies normal EC coupling, that is, calcium-induced calcium release. Finally, the oscillatory changes in intracellular calcium induce oscillatory inward current.

![Fig. 2. Top: action potentials computed using a model of a guinea-pig ventricular cell. Middle: calcium current $i_{CaL}$. Bottom: potassium current $i_{Kr}$. A 65% block of the fast component of $i_K$ prevents repolarization and generates multiple after-depolarizations (12).](image)
Computational Models of the Heart

Figure 6 shows an example of this phenomenon in an atrial cell model. Only some of the cell models succeed in reproducing this phenomenon, which depends critically on the equations used to represent calcium-induced calcium release. There are still many gaps in our knowledge of this process (29), particularly concerning the role of sub-sarcolemmal spaces in which the free calcium concentration may reach levels much higher than in the bulk cytosol. This is an area where modelling needs to make much more progress by refining our understanding of the EC coupling process, the role of ‘fuzzy’ spaces, and the mechanisms of calcium signalling within the cell (30).

This is a long cascade of events and therapeutic intervention can therefore be targeted at several different points. Some pharmaceutical approaches focus on the final stage, the generation of depolarizing electric current by sodium-calcium exchange. Inhibitors of sodium-calcium exchange have been developed. The object in this case is either to inhibit the electric current generated by the exchanger or to reduce its contribution to calcium overload in conditions in which it operates in reverse mode. Neither approach has yet proven effective.

It might therefore be better to intervene at an earlier stage in the cascade and attempt to limit one of the earlier stages, that is, sodium overload. This is the approach used in a new class of cardiac drugs that inhibit the persistent sodium current while having little or no effect on the peak sodium current. The first example of such a drug is ranolazine (25). As we have already seen in Fig. 5, inhibition of persistent sodium current is the basis of this compound’s ability to avoid inducing EADs. Figure 7 shows that it would also be expected to reduce sodium loading.

via sodium-calcium exchange that, if large enough, can trigger extra action potentials (ectopic beats). Figure 6 shows an example of this phenomenon in an atrial cell model.

Only some of the cell models succeed in reproducing this phenomenon, which depends critically on the equations used to represent calcium-induced calcium release. There are still many gaps in our knowledge of this process (29), particularly concerning the role of sub-sarcolemmal spaces in which the free calcium concentration may reach levels much higher than in the bulk cytosol. This is an area where modelling needs to make much more progress by refining our understanding of the EC coupling process, the role of ‘fuzzy’ spaces, and the mechanisms of calcium signalling within the cell (30).

This is a long cascade of events and therapeutic intervention can therefore be targeted at several different points. Some pharmaceutical approaches focus on the final stage, the generation of depolarizing electric current by sodium-calcium exchange. Inhibitors of sodium-calcium exchange have been developed. The object in this case is either to inhibit the electric current generated by the exchanger or to reduce its contribution to calcium overload in conditions in which it operates in reverse mode. Neither approach has yet proven effective.

It might therefore be better to intervene at an earlier stage in the cascade and attempt to limit one of the earlier stages, that is, sodium overload. This is the approach used in a new class of cardiac drugs that inhibit the persistent sodium current while having little or no effect on the peak sodium current. The first example of such a drug is ranolazine (25). As we have already seen in Fig. 5, inhibition of persistent sodium current is the basis of this compound’s ability to avoid inducing EADs. Figure 7 shows that it would also be expected to reduce sodium loading.
The top traces are experimental recordings from the work of Boyett et al. (31) showing the rise in intracellular sodium in a sheep Purkinje fibre on stimulating repetitively after a long period of rest. Over a period of 400 s intracellular sodium activity increases from under 6 mM to about 8 mM. The lower traces show much the same degree of rise in internal sodium in the ventricular cell model. A repeat of the computation with the persistent sodium current fully blocked reduces the sodium loading, in this case by about 30%.

This mechanism is thought to be the basis of the therapeutic effect of this compound in cardiac ischemia, since one of the main causes of arrhythmia in this condition is attributable to sodium overload.

The exact mechanisms of arrhythmia during sodium overload conditions, such as those occurring during ischemia and heart failure, remain to be worked out. The mechanism reproduced here is just one example of a possible process by which arrhythmia could occur.

**Linking levels: building the virtual heart**

Although many of the mechanisms of cardiac arrhythmia can be studied and modelled at the cellular level, the question whether an arrhythmia is likely to be fatal requires analysis at multicellular levels, including that of the whole organ. A few ectopic beats, or a period of tachycardia may be survived, but if a re-entrant arrhythmia breaks down into fibrillation then it is usually fatal. The incorporation of the cellular models
into models of cardiac tissue and of the whole organ is therefore essential. I have been privileged to collaborate with several of the key people involved in extending cardiac modelling to levels higher than the cell. The earliest work was with Raimond Winslow who used the Connection Machine at Minnesota, a huge parallel computer with 64,000 processors. We were able to construct models in which up to this number of cell models were connected together to form 2D or 3D blocks of atrial or ventricular tissue. This enabled us to study the factors determining whether ectopic beats generated during sodium overload would propagate across the tissue (32) and to study the possible interactions between sinus node and atrial cells (33).

Extension to the level of the whole organ came in collaboration with the University of Auckland where Peter Hunter, Bruce Smaill and their colleagues in bioengineering and physiology constructed the first
anatomically-detailed models of a whole ventricle, including mechanics. These models include fibre orientations and sheet structure (34, 35), and have been used to incorporate the cellular models in an attempt to reconstruct the electrical and mechanical behavior of the whole organ.

This work includes simulation of the activation wavefront (36, 37). This wavefront is heavily influenced by cardiac ultra-structure, with preferential conduction along the fiber-sheet axes, and the results correspond well with that obtained from multi-electrode recording from dog hearts in situ. Accurate reconstruction of the depolarization wavefront promises to provide reconstruction of the early phases of the ECG to complement work already done on the late phases (15) and as the sinus node, atrium, and conducting system are incorporated into the whole heart model (38) we can look forward to the first example of reconstruction of a complete physiological process from the level of protein function right up to routine clinical observation.

The whole ventricular model has already been incorporated into a virtual torso (39), including the electrical conducting properties of the different tissues, to extend the external field computations to reconstruction of multiple-lead chest and limb recording. Incorporation of biophysically detailed cell models into whole organ models (35, 37, 40, 41) is still at an early stage of development, but it is essential to attempts to understand heart arrhythmias. So also is the extension of modelling to human cells (42, 43).

Work at the level of the whole ventricle has progressed rapidly as the necessary computing power has become available. This includes reconstructing some of the arrhythmic processes occurring during ischemia (44), the mechanisms of breakdown into fibrillation (45), modelling of the coronary circulation (46), and the mechanisms of defibrillation (41).

The multicellular and whole organ models are beginning also to be used in understanding the actions of drugs. A good example of this work within the BioSim network comes from Arun Holden’s laboratory in Leeds. Figure 9 shows reconstruction of the spread of ectopic excitation in a model of the left ventricular wall. This work has been used to define the liminal volume necessary for an ectopic focus to initiate a fully conducted wave of excitation.

These models have been used to study the mechanisms of arrhythmogenesis (47, 48) and to study the actions of drugs such as d-sotalol on propagation (47). We can therefore look forward to testing the actions of drugs at multiple levels including that of the whole heart.

One of the main causes of cardiac arrhythmia is ischemia. Ischemia displays a high degree of heterogeneity so that multicellular simulations are necessary to represent the full impact of ischemia. Electrophysiological properties vary not only with time post-occlusion, but also spatially. Due to diffusion of ions and metabolites, the core of the tissue suffering from a lack of flow, that is the central ischemic zone (CIZ), is surrounded by border zones (BZ), which comprise progressive changes in electrophysiological properties between the healthy and ischemic regions. Experimental measurements of $[K^+]_o$ oxygen, and metabolite distribution in the ischemic area (49-53) were used by Ferrero et al. (54) to develop the 2D model of regional ischemia depicted in Fig. 10A, which included the first electrophysiologically detailed model of the BZ. Ischemia was represented by the effects of hyperkalemia, acidosis, and hypoxia on $[K^+]_o$, $I_{Na}$, $I_{CaL}$, and $I_{KATP}$, at levels corresponding to 10-min post-occlusion.

The severity of ischemic changes is most pronounced within the CIZ and decreases progressively in the BZ. The varying levels of $[K^+]_o$, $I_{Na}$, $I_{CaL}$ and $I_{KATP}$ in the ischemic region result in a significant dispersion of refractoriness and of conduction velocity by the mechanisms explained in (44). Figure 10B shows the spatial variation of conduction velocity, APD, and effective refractory period in the border zone, as quantified by Ferrero et al. (54). Dispersion of refractoriness and of conduction velocity in regional ischemia provides the substrate for the establishment of reentrant circuits, the main mechanism of arrhythmogenesis following coronary occlusion (53, 55, 56).

Figure 10C illustrates the initiation of a figure-of-eight reentry in this model of regional ischemia. Following pacing stimulation, a premature stimulus is applied at the bottom border of the 2D sheet. The premature stimulus elicits a wavefront, which propagates through the healthy region as well as the BZs, but blocks at the CIZ where refractoriness is extended. Meanwhile, tissue in the CIZ recovers, allowing reentry of the wavefront from the top, and the establishment of a figure-of-eight reentrant circuit, a pattern similar to the one observed experimentally (57-60). Simulation results shows that the degree of activation of the $I_{KATP}$ plays an important role in vulnerability to reentry in regional ischemia (54, 61).

Simulation of disease states like ischemia will enable the study of drug interactions with various forms of disease-induced arrhythmia. One of the problems with computation at this level is that of computing resources. Even quite short simulations can require many hours of time on supercomputers. Work is progressing in attempting to solve these problems using more powerful computers and using networks of computers. We can therefore look forward to the day when it will be
Fig. 9. Snapshots of orthotropic propagation of a single wave through a wedge model of the human end-diastolic (resting) left ventricular free wall, from an ectopic focus located on the endocardial surface. Spatially heterogeneous excitation kinetics are described using the ten Tusscher-Noble-Noble-Panfilov model (40), with endocardial, midmyocardial, and epicardial tissue occupying approximately equal fractions of the transmural distance. The diffusion coefficient in the fiber axis direction was set to 0.154 mm$^2$ ms$^{-1}$, with a ratio of 36:9:1 in the fiber axis, sheet, and sheet normal directions, respectively, to give a conduction velocity ratio of 6:3:1. Top panels show a view from the epicardial aspect, and bottom panels show a transmural view with the endocardium on the left and the epicardium on the right. The spatial extent of the wedge geometry is indicated in light blue, and excited tissue is in red. Times indicate duration since initial propagation from the ectopic focus. The architecture of the ventricular wall tissue results in complex wavefront geometries due to the rotational orthotropy inherent in the tissue. The wedge geometry and architecture was extracted from a human DT-MRI dataset provided by P.A. Helm and R.L. Winslow at the Center for Cardiovascular Bioinformatics and Modeling and E. McVeigh at the National Institute of Health (from Ref. 43).

Fig. 10. Arrhythmogenesis in regional ischemia. Panel A: Schematic of the 2D model of regionally ischemic tissue (left) and the spatial variations in extracellular potassium concentration ([K$_+^+$]), intracellular ATP and ADP concentrations ([ATP]$_i$ and [ADP]$_i$), and the degree of inhibition of the maximum conductances of the Na$^+$ and Ca$^{2+}$ currents in the central ischemic zone (CIZ), border zone (BZ), and normal zone (NZ) (right). Panel B: Spatial variation in the effective refractory period and action potential duration (left) and in the longitudinal conduction velocity (right) along the dashed line depicted in panel A, left. Panel C: Snapshots of transmembrane potential distribution at different instants of time following the delivery of a premature stimulus at CI = 210 ms in the lower part of the 2D sheet illustrated in panel A. Snapshots are separated by 50 ms; the first corresponds to 50 ms after the delivery of the premature stimulus. Modified from Ferrero et al. (45).
possible to have a complete suite of simulations in drug discovery and drug-testing running all the way from drug–receptor interactions to function in the whole organ.

Acknowledgments

Work in the author’s laboratory is supported by EU FP6 BioSim network of excellence, EU FP7 PreDiCT project, The Wellcome Trust and the British Heart Foundation.

References


37 Noble D. Modelling the heart: from genes to cells to the whole organ. Science. 2002;295:1678–1682.


